Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aclaris Therapeutics, Inc. (NASDAQ: ACRS).

Full DD Report for ACRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACRS)

Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
WAYNE, Pa., May 16, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and imm...
Source: GlobeNewswire
Date: May, 16 2018 07:00
Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting
WAYNE, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and imm...
Source: GlobeNewswire
Date: May, 15 2018 07:00
Aclaris Therapeutics' (ACRS) CEO Neal Walker on Q1 2018 Results - Earnings Call Transcript
Aclaris Therapeutics, Inc. (ACRS) Q1 2018 Earnings Conference Call May 08, 2018, 17:00 ET Executives Kamil Ali-Jackson - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary Neal Walker - Co-Founder, CEO, President & Director Brett Fair - Chief Commercial...
Source: SeekingAlpha
Date: May, 13 2018 00:42
Aclaris Therapeutics to Present at the 2018 American Hair Research Summit
WAYNE, Pa., May 11, 2018 (GLOBE NEWSWIRE) -- Paul Changelian, Ph.D., Vice President, Biology, Aclaris Therapeutics, Inc. (NASDAQ:ACRS), will speak at the 2018 American Hair Research Summit on “Preclinical to Clinical Translation of JAK Kinase Inhibitors" on May 15. The meeting is org...
Source: GlobeNewswire
Date: May, 11 2018 07:00
Aclaris Therapeutics beats by $0.02, beats on revenue
Aclaris Therapeutics (NASDAQ: ACRS ): Q1 EPS of -$0.98 beats by $0.02 . More news on: Aclaris Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:20
Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
• Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies ...
Source: GlobeNewswire
Date: May, 08 2018 16:01
Aclaris Therapeutics Announces Availability of ESKATA(TM) (Hydrogen Peroxide) Topical Solution, 40% (w/w)
MALVERN, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase by dermatologists in the United States. ESKATA is the first and only FDA-approved to...
Source: GlobeNewswire
Date: May, 07 2018 10:00
Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee
WAYNE, Pa., April 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and i...
Source: GlobeNewswire
Date: April, 24 2018 16:05
Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
WAYNE, Pa., April 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and i...
Source: GlobeNewswire
Date: April, 24 2018 16:05
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
Analysis focus: Roche Today we will discuss Roche (RHHBY), after the company announced data with its multiple sclerosis ((MS)) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver...
Source: SeekingAlpha
Date: April, 24 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1719.4919.6419.8219.45143,736
2017-06-2025.7326.0626.5425.25263,156
2017-06-1925.5625.7626.38525.28291,847
2017-06-1625.0025.4925.9624.76511,777
2017-06-1524.9824.5825.46524.31257,733

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-166,34733,47418.9610Cover
2018-08-1525,35488,29828.7141Cover
2018-08-144,82613,53435.6583Short
2018-08-139,14460,85115.0269Cover
2018-08-107,47525,18229.6839Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACRS.


About Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

Logo for Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

Aclaris Therapeutics, Inc. is a clinical stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology

 

Contact Information

 

 

Current Management

  • Neal Walker / President, CEO
  • Frank Ruffo / CFO
  • Christopher Powala / CCO
  • Neal Walker /

Current Share Structure

  • Market Cap: $600,725,004 - 05/14/2018
  • Issue and Outstanding: 30,901,492 - 03/09/2018

 


Recent Filings from (NASDAQ: ACRS)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ACRS)

Daily Technical Chart for (NASDAQ: ACRS)


Stay tuned for daily updates and more on (NASDAQ: ACRS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACRS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ACRS and does not buy, sell, or trade any shares of ACRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/